Having just crossed my one year threshold as an investor in CYDY and reflecting back over it, one thing stands in the foreground in a very powerful way: Everything concerning the advancement of leromlimab as a therapeutic has taken way longer than any of us ever thought it would.

So to answer your question C I will continue what I have been doing this past year, and what other investors have been doing for several year's, I will simply wait.